Literature DB >> 9507390

Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes.

J Chang-Claude1, J Dong, S Schmidt, M Shayeghi, D Komitowski, H Becher, M R Stratton, B Royer-Pokora.   

Abstract

Germline mutations in highly penetrant autosomal dominant genes explain about 5% of all breast cancer, and heritable mutations in the BRCA1 breast and ovarian cancer susceptibility gene account for 2-3% of breast cancer in the general population. Nevertheless, the presence of such mutations is highly predictive of disease development. Since screening for mutations is still technically laborious, we investigated whether the prior probability of being a carrier of a dominant breast cancer susceptibility gene in the youngest affected family member could be used to identify families in which the probability of finding a mutation is sufficiently high. Sixty German families with three or more cases of breast/ovarian cancer with at least two cases diagnosed under the age of 60 were screened for mutations by SSCP/CSGE and subsequent direct sequencing. Thirteen germline truncating/splicing mutations in BRCA1 were found in 33% (6/18) of the breast-ovarian cancer families and in 17% (7/42) of breast cancer only families. All the families showing mutations in BRCA1 had carrier probabilities of 0.65 or higher. In families with prior carrier probabilities above 0.6, the proportion detected was 0.46 in breast-ovarian cancer families and 0.26 in breast cancer only families. The average age at diagnosis of breast or ovarian cancer in families with BRCA1 mutations was 41.9 years and significantly lower than in families without mutations (p < 0.05). Mutation carriers and obligate carriers were also found to have cancers at other sites. The probability of being a susceptibility gene carrier, taking into account the complete pedigree information, allows uniform characterisation of all types of families for identifying those in which mutation analysis for BRCA1/2 is warranted. However, prior probabilities calculated using this method can be reduced when the correlation between genotype and phenotype is imperfect. A larger series of families needs to be investigated in this fashion to provide better estimates of the detection rate for different ranges of carrier probabilities.

Entities:  

Mesh:

Year:  1998        PMID: 9507390      PMCID: PMC1051214          DOI: 10.1136/jmg.35.2.116

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  33 in total

1.  Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.

Authors:  M Goggins; M Schutte; J Lu; C A Moskaluk; C L Weinstein; G M Petersen; C J Yeo; C E Jackson; H T Lynch; R H Hruban; S E Kern
Journal:  Cancer Res       Date:  1996-12-01       Impact factor: 12.701

2.  The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals.

Authors:  J P Struewing; D Abeliovich; T Peretz; N Avishai; M M Kaback; F S Collins; L C Brody
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

Review 3.  Familial risk and genetic susceptibility for breast cancer.

Authors:  N Eby; J Chang-Claude; D T Bishop
Journal:  Cancer Causes Control       Date:  1994-09       Impact factor: 2.506

4.  Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families.

Authors:  L S Friedman; E A Ostermeyer; C I Szabo; P Dowd; E D Lynch; S E Rowell; M C King
Journal:  Nat Genet       Date:  1994-12       Impact factor: 38.330

5.  Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer.

Authors:  L H Castilla; F J Couch; M R Erdos; K F Hoskins; K Calzone; J E Garber; J Boyd; M B Lubin; M L Deshano; L C Brody
Journal:  Nat Genet       Date:  1994-12       Impact factor: 38.330

6.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

Authors:  D F Easton; D Ford; D T Bishop
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

7.  Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13.

Authors:  J Gudmundsson; G Johannesdottir; J T Bergthorsson; A Arason; S Ingvarsson; V Egilsson; R B Barkardottir
Journal:  Cancer Res       Date:  1995-11-01       Impact factor: 12.701

8.  A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening.

Authors:  D Shattuck-Eidens; M McClure; J Simard; F Labrie; S Narod; F Couch; K Hoskins; B Weber; L Castilla; M Erdos
Journal:  JAMA       Date:  1995-02-15       Impact factor: 56.272

9.  Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence.

Authors:  D Ford; D F Easton; J Peto
Journal:  Am J Hum Genet       Date:  1995-12       Impact factor: 11.025

10.  Genetic counselling in breast cancer: sensitivity to parameter values and to available information.

Authors:  P Margaritte-Jeannin; L Essioux; C Bonaïti-Pellié; F Clerget-Darpoux
Journal:  Ann Genet       Date:  1995
View more
  7 in total

1.  Computer support for genetic advice in primary care.

Authors:  J Emery
Journal:  Br J Gen Pract       Date:  1999-07       Impact factor: 5.386

2.  Mutation detection in the breast cancer gene BRCA1 using the protein truncation test.

Authors:  W Moore; I Bogdarina; U A Patel; M Perry; C Crane-Robinson
Journal:  Mol Biotechnol       Date:  2000-02       Impact factor: 2.695

Review 3.  Why should primary care physicians know about breast cancer genetics?

Authors:  L E Pinsky; J B Culver; J Hull; E Levy-Lahad; M Daly; W Burke
Journal:  West J Med       Date:  2001-09

4.  Increased variation in mtDNA in patients with familial sensorineural hearing impairment.

Authors:  Mervi S Lehtonen; Jukka S Moilanen; Kari Majamaa
Journal:  Hum Genet       Date:  2003-06-12       Impact factor: 4.132

Review 5.  The pathology of familial breast cancer: Clinical and genetic counselling implications of breast cancer pathology.

Authors:  F Lalloo; D G Evans
Journal:  Breast Cancer Res       Date:  1999-10-27       Impact factor: 6.466

6.  Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families.

Authors:  Hannaleena Eerola; Päivi Heikkilä; Anitta Tamminen; Kristiina Aittomäki; Carl Blomqvist; Heli Nevanlinna
Journal:  Breast Cancer Res       Date:  2005-04-21       Impact factor: 6.466

7.  Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families.

Authors:  Hannaleena Eerola; Päivi Heikkilä; Anitta Tamminen; Kristiina Aittomäki; Carl Blomqvist; Heli Nevanlinna
Journal:  Breast Cancer Res       Date:  2004-11-19       Impact factor: 6.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.